Get started

Smallcap

DOC.C - Telemedicine services in high demand during the pandemicCloudMD Reaches Over 100,000 Registered Users on Telemedicine Platform VANCOUVER, British Columbia, April 07, 2020 (GLOBE NEWSWIRE) -- CloudMD Software & Services Inc. (CSE: DOC, OTCQB: DOCRF, Frankfurt: 6PH) (the “Company” or “CloudMD”), a telemedicine company revolutionizing the delivery of healthcare to patients, is excited to announce that it has reached over 100,000 registered users combined on its CloudMD and MyHealthAccess telemedicine platforms. To date, CloudMD has grown its platform of registered users organically and a large part of its customer acquisition has come from referrals from its network of doctors in Canada. Patients on both platforms have easy access to the extended hours, 7 day week coverage provided by the CloudMD doctors. Since its launch in February 2020, CloudMD has grown its platform by almost 10,000 app downloads. During the last two weeks, approximately 1000 virtual doctors appointments were booked on the CloudMD platform, growth of over 3x compared to the previous period. Combined registration on both platforms have also increased 133% over the last week, as more people remain in isolation and cannot attend in-person medical appointments. With the recent COVID-19 pandemic, CloudMD offers Canadians an alternative to in-person visits to crowded or closed medical clinics. Patients can now download the CloudMD app and schedule a same day appointment online and connect directly with a licensed physician on their phone, tablet, or computer from the comfort of their home. Dr. Essam Hamza, CEO of CloudMD commented, “CloudMD continues to revolutionize the way healthcare is delivered to patients. We are excited and encouraged by the continued growth of our CloudMD platform as the significant increase in registered users continues to reinforce buy-in from the communities we serve.” He continued, “During these difficult times we are proud to offer much needed and timely medical care to the Canadian population. We remain committed to providing the best health care services to our patients.” CloudMD also announces it has engaged Strike Communication Inc. (“Strike”) to manage investor relations and corporate development strategies. Strike is a boutique capital markets advisory firm based in Vancouver, BC. As part of its compensation, Strike will be granted incentive stock options exercisable to purchase up to 150,000 common shares in the capital of the Company at an exercise price of $0.50 per share for a period of five years. 100% of the incentive stock options will vest 12 months after the grant.
DLong
by agstockpicks
NSP.V -- Ensuring food supply in BC during Coronavirus outbreakNSP.V is helping to ensure stable food supply in BC and has applied for government funding to retool and to up its production. Also offering natural anti-viral and anti-bacterial supplements based on curcumin that may help in preventing spread of COVID-19. The stock is cheap at $4.24 M and is reversing after prolonged downtrend. Bottom .025 has been tested and held multiple times. Buyers are stepping in in recent days as confirmed by bullish MACD cross and RSI/Stoch action. Very good chance of a bounce from current levels (.03), IMO
NLong
by agstockpicks
2
GGG.V -- Air filtration equipment to fight spread of virusesPulled out of overbought area and filled the gap. Fib. support at .09. Strong volume. I am in at .09. --------------------------------------------------------------------------------------------------------------------------- G6 Materials Corp. Develops Disinfection Products to Fight the Spread of COVID-19 April 1, 2020 - TheNewswire - Ronkonkoma, NY USA - G6 Materials Corp (the "Company" or "G6," (TSXV:GGG) (OTC:GPHBF) is pleased to provide an update from its Research & Development department. The outbreak of the COVID-19 has drastically altered the economic landscape, and G6 management is optimizing the business model to accommodate the new reality, addressing these new business opportunities. The CEO of the Company, Daniel Stolyarov, explains, “There is an imminent demand for solutions that allow for the removal of viruses from the air and surfaces increasing the safety of the immediate environment. The Company has prioritized work in this sector and plans to address these market needs immediately.” The Company's Research & Development Department has developed a solution for air purification products that are designed to mitigate the threat of virus infection in confined spaces such as offices and industrial warehouses. There is substantial scientific evidence of antiviral and antibacterial effectiveness of graphene coatings. The Company has found a unique method to incorporate graphene in the air filtration systems making them more efficient in killing germs. The Company is currently conducting internal testing, and will subsequently apply for appropriate accreditations. The applications of this solution are numerous. Such systems can be included in existing HVAC systems or included in the design of new ones. They can be combined with conventional filtration methods as well as UV irradiation. Any large scale structures, including office buildings and factories, could all be the benefactor of this system. Stolyarov continues, “Economies all around the world are experiencing unprecedented disruption due to the COVID-19 situation, leaving a long-lasting impact. We hope that the quarantine measures prove effective in stemming the spread of the virus, but quarantines cannot last forever. When people return to work they will demand that their work environment is safe. We provide a solution to this problem". The Company will continue testing of the prototypes and is actively looking for an industrial partner to rapidly expand the manufacturing capability and bring these highly demanded products to market.
G
by agstockpicks
VS.C -- eSports and Video Streaming Rewards PlatformVS.C is approaching the eSports sector the right way with its proprietary rewards platform that integrates into applications, games and streaming services. This is one of the sectors that is thriving during the coronavirus pandemic. The company keeps delivering on growth and has just announced an expansion into streaming video via Kast. Haywood analyst gives it a BUY rating with a .55 price target. Technically, the stock has been heavily accumulated in recent months. The selldown in the last few days was likely a short attack targeting the .185 - .195 gap. It failed but I used it as an opportunity to build a position at .22 average. Given the string of positive news releases and the extension of the .40 warrants that was just announced, I expect that the company will make a promotional push to try and get them exercised. But even without promo, the stock should be trading a fair bit higher based on the business growth/expansion. It's one of those rare times when I do agree with the institutional analysts.
VLong
by agstockpicks
1
IPA.V - Agreement with Johnson & Johnson for Coronavirus vaccineIPA.V appears to have entered into agreement with Johnson & Johnson's subsidiary to develop the Coronavirus vaccine. The market is asleep due to cryptically worded news release. Connecting the dots... --------------------------------------------------------------------------------------------------------------------------------------- ImmunoPrecise Announces Agreement with Janssen VICTORIA and CAMBRIDGE, MA, April 14, 2020 /PRNewswire/ - IMMUNOPRECISE ANTIBODIES LTD. (the "Company" or "IPA") (TSX VENTURE: IPA) (OTC QB: IPATF), a global leader in therapeutic antibody discovery and development, announced that it, through its subsidiary Talem Therapeutics, has entered into a research license agreement (the "Agreement") with Janssen Research & Development, LLC ("Janssen"), providing Janssen exclusive access to a panel of novel, monoclonal antibodies against an undisclosed target. Pursuant to the Agreement, Janssen holds an option to acquire all commercial rights to the antibodies. The financial details of the transaction have not been disclosed. "This Agreement validates Talem's business concept in early antibody discovery and development," said Ilse Roodink, Chairwoman of Talem's Scientific Advisory Committee and Scientific Director at IPA Europe. "It is a significant milestone to see this exclusive agreement through Talem finalized with Janssen, a company so well positioned to further develop and maximize the potential of these lead candidates for clinical applications." "Talem continues to build a therapeutic program pipeline for commercial partnering, thus optimizing shareholder value creation based on IPA's infrastructure across Europe and North America," added Jennifer Bath, President and CEO of IPA. --------------------------------------------------------------------------------------------------------------------------------------- The U.S. Just Signed A $450 Million Coronavirus Vaccine Contract With Johnson & Johnson The Trump administration is spending nearly half a billion dollars on one company in the race to find a coronavirus vaccine. That’s according to a $456 million order with Johnson & Johnson’s Pharmaceuticals arm Janssen, which specified a “new vaccine asset for 2019 Novel Coronavirus (COVID-19),” Forbes found. It’s the largest reported amount spent on a vaccine project to date, even though the pharma giant hasn’t yet started any clinical trials as other firms have. The deal was signed with the Health and Human Services Office of the Assistant Secretary for Preparedness and Response (ASPR) on March 27, 2020. It followed another order, made as part of the same contract with Janssen, for $150 million on March 20, 2020, for a “new antiviral” for COVID-19. A spokesperson from Johnson & Johnson didn’t provide any more details on the specific order, but confirmed the $456 million award related to a collaboration with ASPR’s Biomedical Advanced Research and Development Authority (BARDA), as announced in February. That work was built on previous contracts for developing countermeasures for other influenzas. The value of the coronavirus-specific work hadn’t previously been revealed and is the largest known contract for a coronavirus vaccine to date. It forms part of a deal between the U.S. government and Johnson & Johnson to co-invest $1 billion into vaccine research, development and clinical testing. The company says it now expects human clinical studies for its vaccine candidate to go ahead, at the latest, by September 2020. It anticipates the first batches of vaccine to be available for emergency use in early 2021.
ILong
by agstockpicks
1
GSI.V Video systems for smart cities; essential business statusStrong accumulation. Bullish MACD cross. Bullish Stoch/RSI action. I am in at .15. --------------------------------------------------------------------------------------------------------------------- Gatekeeper Operating as Essential Business During COVID-19 Outbreak Abbotsford, BC - TheNewswire - April 6, 2020 - Gatekeeper Systems Inc. (‘Gatekeeper’ or the ‘Company’) (TSXV:GSI) (OTC:GKPRF) (FSE:1GK) a leading provider of intelligent video solutions for public transport and smart cities, provides a corporate update relating to its operations during the COVID-19 outbreak. Gatekeeper, through its subsidiary Gatekeeper Systems USA Inc., has been deemed an essential business during the emergency order which temporarily prohibits operation of non-essential businesses in Pennsylvania. The Company’s business relating to the Southeastern Pennsylvania Transportation Authority (SEPTA) continues normal operations. SEPTA is the Company’s largest customer and represented approximately 30% of the Company’s revenues during its 2019 fiscal year. The Company reports no material change in its contract with SEPTA announced on October 17, 2019 to provide annually recurring services valued at approximately $2.36 million per year. The Company reports no material change in its contract with SEPTA announced on October 9, 2019 to supply and install digital video recorders on SEPTA vehicles and trains in a contract valued at approximately $6.3 million. This contract is expected to be billed during the second half of the Company’s fiscal year which ends August 31, 2020. Gatekeeper has adjusted its business operations during the COVID-19 outbreak to firstly ensure the safety of its employees as its top priority. Protection procedures for service technicians have been implemented and office employees are working from home where possible. The Company is also working with its suppliers and customers during this period of business disruption to ensure continuity of business operations where possible. The Company will report its financial results for its second quarter ended Feb 29, 2020 by the prescribed filing due date of April 29, 2020. Gatekeeper also announces that it has granted an aggregate of 675,000 incentive stock options to certain directors, officers, employees and consultants under the Company’s stock option plan, subject to regulatory approval. The stock options are exercisable at a price of $0.135 for a period of five years from the date of grant and subject to vesting provisions.
TSXV:GSILong
by agstockpicks
AGN.C -- Coronavirus Treatment Spec; Phase 2 Clinical Trial newsAnother CoronaVirus spec play. Pulled back from recent highs and trading in the support band, for now. I bought in at .20 - .21 today. $18M mkt cap. 90M float. Could see a nice run on today's news: Algernon to Support Planned Phase 2 Trial of Ifenprodil for Coronavirus VANCOUVER, British Columbia, March 19, 2020 (GLOBE NEWSWIRE) -- Algernon Pharmaceuticals Inc. (CSE: AGN) (FRANKFURT: AGW) (OTCQB: AGNPF) (the “Company” or “Algernon”) a clinical stage pharmaceutical development company is pleased to announce that Novotech, a leading Asia-Pacific clinical research organization (CRO), has identified physicians in South Korea who have agreed to conduct an investigator initiated phase 2 clinical trial of Ifenprodil for coronavirus patients. The investigators were identified after Algernon retained Novotech to conduct a feasibility study in South Korea. Novotech was asked to advise on the most efficient regulatory approach to initiating a phase 2 clinical trial for Ifenprodil for COVID-19 and to also help identify potential investigators. Ifenprodil is an already approved drug in South Korea and Japan for certain neurological conditions with a known safety history. Algernon has been investigating Ifenprodil under its re-purposed drug program and has appointed Novotech as the lead CRO for its upcoming idiopathic pulmonary fibrosis (IPF) and chronic cough phase 2 clinical trial to be conducted in Australia. The Company is in the process of refining the protocol for the phase 2 coronavirus study after receiving input from the investigators, and is working with Novotech to provide the necessary information and support in order to assist with the study’s approval. The study approval process may be expedited due to the current global health crisis. The Company will release more information about the planned phase 2 coronavirus study shortly. The decision to retain Novotech to conduct a feasibility study was made after a recent independent study found that Ifenprodil significantly reduced acute lung injury (ALI) and improved survivability in an animal study with Asian H5N1 infected mice by 40%. Asian H5N1 is the most lethal form of influenza known to date with an over 50% mortality rate. The drug was also previously shown in a separate study to prolong survival under anoxic (low oxygen) conditions, as might occur in patients with severely impaired lung function. “This independent study data, along with the data generated from the Company’s animal studies on IPF and chronic cough, have supported the Company’s recent new COVID-19 and acute lung injury clinical program,” said Christopher J. Moreau CEO of Algernon Pharmaceuticals.
CSE:AGNLong
by agstockpicks
LBL.V -- Stem cell based CoronaVirus treatment; VOLUME!LBL.V is hitting highest volume on TSX-V today. Very similar setup to VXL.V from last week, just before it made the big move from .14 to .325 but cheaper and much better financials. Cash flow positive. $8.4M market cap. 93M shares out. See the most recent news release with regards to positive outcomes in applying their technology to treat the Coronavirus patients in China: "Recently published results from an investigator-initiated clinical study conducted in China which reported that allogeneic mesenchymal stem cells (MSCs) cured or significantly improved functional outcomes in all seven treated patients with severe COVID-19 pneumonia." Google "Lattice Biologics to Evaluate Anti-Inflammatory Stem Cell Therapy Treatment of COVID-19 Lung Disease"
LLong
by agstockpicks
1
YouGov - Correction over, new highs expected.Buy YouGov (YOU.L) YouGov plc is a United Kingdom-based international data and analytics company. The Company’s suite of products and services is made up of syndicated data products including YouGov BrandIndex and YouGov Profiles and data services including YouGov Omnibus and YouGovCustom Research. YouGov BrandIndex is a daily brand perception tracker. YouGov Profiles is its planning and segmentation tool. YouGov Omnibus finds out people's opinions, attitudes and behaviors. YouGov Custom Research conducts quantitative and qualitative research. The company has 35 offices in 22 countries. Market Cap: £546Million YouGov is trading in a fantastic long-term uptrend. The shares have recently corrected from fresh all-time highs at 616p and appear to have found some support at the uptrend support line. The shares are on the move higher today, the close above the 10EMA could be a sign that the corrective move lower has come to an end and that further upside can be expected over the medium to long term. We are targeting a move to fresh all-time highs at 700p. Stop: 504p Target: 700p Interested in UK Small Caps? Join our free Telegram channel for up to date analysis on the best small-cap opportunities in the UK right now. t.me
LSE:YOULong
by Investamate
EW.V -- Low risk bottom fishing opp; trading at cash valueAn incredible opportunity to buy EW.V at cash value. With JV partner in Romania covering 100% of the exploration costs, this could become a multi-bagger if any of the wells being tested are deemed commercial. EW.V is getting 15% of any oil that spuds. The stock has found a bottom at .055 in the past 2 weeks with bid support steadily increasing. Bullish divergence with MACD/RSI/Stochastic indicators points to a likely near-term breakout. I am long at .055 - .065. ASSETS Cash: $3,719,020 GST Receivable: $7,923 Amounts Receivable: $223,772 Prepaid Expenses: $22,654 Investments: $554,709 Assets Held For Sale: $2,067,867 Total Assets: $6,595,945 LIABILITIES Accounts Payable: $206,404 Decommissioning Liability: $309,904 Liabilities On Asset Held For Sale: $943,472 Deposit: $65,505 Total Liabilities: $1,525,285 NAV $6,595,945 - $1,525,285 = $5,070,660
TSXV:EWLong
by agstockpicks
ESPT.V On Watch for Downtrend Pattern Breakout (eSports/Gaming)ESPT.V lit up a nice green candle on the daily chart to end the week. Poked its head above the downtrend channel that started on Aug 20th for the first time. The company is one of the early movers in the rapidly growing #eSports sector and is expected to close a revenue-generating acquisition within 1 - 2 weeks, followed by another major acquisition. Both were paid in .30 shares. Currently trading at .225. Very bullish macro environment. Latest RBC Wealth Management report shows #Gaming #eSports sectors are in the early bull cycle. ESPT.V is one of the better values with $2.3M in revenues last year, $9M mkt cap and 43M float. Catchy ticker name is a bonus. :)
ELong
by agstockpicks
48North - The Small Cap Cannabis Company To WatchI have maintained a long thesis on 48North Cannabis Corporation since October 2018, and the trade worked wonderfully into March of last year. However, 48North pulled back alongside the entire cannabis sector, and rightfully so on some of their own missteps. As a brief introduction, I believe 48North's competitive advantage stems from their outdoor grow operation, creating a low cost of goods operating model that will enable 48North to price products competitively and reward investors with higher gross margin performance when compared against the peer group. It should be noted that 48North missed their production guidance for 2019- resulting from delayed licensing for drying rooms. In 2019 48North demonstrated that outdoor grown cannabis can be completed at scale, at a low cost, and successfully pass Health Canada's quality control standards. From a chart perspective I'm considering the Elliott Wave ABC pattern to be completed with a clean retracement & double bottom at $0.315 - neatly correlating with the 161.8 fib extension of Wave A Current Market Cap: $63M Cash on Hand: $40M It is my opinion that 48North's cash position reduces the need for any capital injection through 2020. Frankly- it is going to be in the hands of 48North to demonstrate in 2020 that they truly can achieve their projected outdoor harvest numbers with drying capacity not being a barrier in 2020.
NLong
by tomthetrader1
8
Trans-Siberian Gold - Breaking from a wedgeBuy Trans-Siberian Gold (TSG.L) Trans-Siberian Gold plc is a United Kingdom-based resource company engaged in acquiring and developing a portfolio of gold mining assets in Russia. The Company's subsidiary, ZAO Trevozhnoye Zarevo (TZ), holds approximately 20 square kilometers of mining license in the southern part of the Kamchatka peninsula, including the Asacha gold deposit, an epithermal gold/silver deposit located on a tertiary volcanic arc typical of ore systems found along the Pacific Rim. The main ore zone at Asacha consists of approximately five steeply dipping veins with over two principal veins averaging over two meters in width. Market Cap: £90.21Million The Trans-Siberian share price has been steadily increasing since the beginning of 2019. The shares reached new all-time highs at 133p before correcting sharply. The corrective move lower has stalled around the 50% Fibonacci level at 90.5p. The consolidation has formed a wedge on the daily chart, which has now broken to the upside. We believe this could lead to continuation higher in the short to medium term. Stop: 90p Target 1: 133p Target 2: 150p Interested in UK Small Caps? Join our free Telegram channel for up to date analysis on the best small-cap opportunities in the UK right now. t.me
TLong
by Investamate